REFERENCES
1. Odame I. Developing a Global Agenda for Sickle Cell Disease. Report of an International Symposium and Workshop in Cotonou, Republic of Benin. Am J Prev Med. 2010;38:106.
2. Diallo DA, Guindo A. Sickle cell disease in sub-Saharan Africa: stakes and strategies for control of the disease. Curr Opin Hematol. 2014;21:210-214.
3. Smart LR, Hernandez AG, Ware RE. Sickle cell disease: translating clinical care to low- resource countries through international research collaborations. Semin Hematol. 2018;55:102-112.
4. Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41:398-405.
5. Adewoyin AS. Management of sickle cell disease: a review for physician education in Nigeria (sub-Saharan Africa). Anemia. 2015;10:1155-1498.
6. Mohammed CR, Annick G, Gilbert A, Roselyn A, Chantal D, Stephani G, Eusebe A. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood. 2003;102:834-838.
7. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103:4023-4027.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease– Life expectancy and risk factors for early death. N Engl J Med.1994;330:1639-1644.
9. Mulumba LL, Wilson L. Sickle cell disease among children in Africa: an integrative literature review and global recommendations. Int J Africa Nurs Sci. 2015;3:56-64.
10. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under Five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:1001484.
11. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663-1672.
12. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139:790-
796.
13. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 2002;332:1317-1322.
14. Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics. 2014;134:465-472.
15. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122:1332- 1342.
16. Lobo C, Hankins JS, Moura P, Pinto JC. Hydroxyurea therapy reduces mortality among children with sickle cell disease. Blood. 2010;116:843-843.
17. US Department of health and human services. Evidenced- based management of sickle cell disease: Expert Panel Report, 2014. https://www.nhlbi.nih.gov/guidelines.
18. Mulumba LL, Wilson L. Sickle cell disease among children in Africa: an integrative literature review and global recommendations. Int J Africa Nurs Sci. 2015;3:56-64.
19. Adewoyin AS, Oghuvwu OS, Awodu OA. Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient’s compliance. Afr Health Sci. 2017;17:255-261.
20. Akinyanju OO. A Profile of sickle cell disease in Nigeria. Ann N Y Acad Sci. 1989;565:126-136.
21. Galadanci N, Wudil BJ, Balogun TM, et al. Current sickle cell disease management practices in Nigeria. Int Health. 2014;6:23-28.
22. Ojewunmi OO, Adeyemo TA, Ayinde OC, Iwalokun B, Adekile A. Current perspectives of sickle cell disease in Nigeria: changing the narratives. Expert Rev Hematol. 2019;12:609-620.
23. Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2018;380:121-131.
24. Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile AD. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. Hemoglobin. 2019;43:188-192.
25. Opoka R, Ndugwa C, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. 2017;130:2585-2593.
26. Akinsete A. Experience with hydroxy carbamide use; indications, adverse effects and clinical course at a tertiary are hospital in Lagos. Nig Qrtly J Hosp Med 2019;28:26-30.
27. Ofakunrin AOD, Adekola KU, Oguche S, Okpe ES, Sagay AS. Efficacy and safety of hydroxyurea in the treatment of sickle cell anemia children in Jos, North Central Nigeria. J Trop Pediatr. 2019;66:290-298.
28. Lagunju, I, Brown , BJ, and Sodeinde O. HydroxyUrea lowers transcranial doppler flow velocities in children with sickle cell anemia in a Nigerian cohort. Pediatr Blood Cancer. 2015;62:1587-1591.
29. Lagunju, IO, Brown , BJ, Oyinlade A. Annual stroke incidence in Nigerian with sickle cell disease and elevated TCD velocities treated with hydroxyurea. Pediatr Blood Cancer. 2019;66:27252.
30. Ofakunrin AOD, Adekola K, Okpe ES, et al. Level of utilization and provider-related barriers to hydroxyurea use in the treatment of sickle cell disease in Jos, Nigeria.Blood. 2019;134:1029.
31. Aliyu ZY, Babadoko A, Mamman A. Hydroxyurea utilization in Nigeria, a lesson in Public health. Blood. 2007;110:80.
32. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132:677-683.
33. Freampong KO. Sickle Pan-African Research Consortium(SPARCO): Hydroxyurea SOP; 2019.
34. Luzzatto L, Makani J. Hydroxyurea - An essential medicine for sickle cell disease in Africa. N Engl J Med. 2019;380:187-189.
35. Jain DL, Apte M, Colah R, et al. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatr 2013;50:929-933.
36. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318:96-99.
37. Ware RE. Hydroxycarbamide: clinical aspects. C R Biol. 2013;336:177-182.
38. Adekile AD et al. Hemoglobin F in sickle cell anemia. Birkhauser Verlag. 1993;49:0016- 0027.
39. Park H, Bhatti S, Chakravorty S. Effectiveness of hydroxycarbamide in children with sickle cell disease – Analysis of dose-response metrics in a large birth cohort in a tertiary sickle cell centre. Pediatr Blood Cancer. 2019;66:27615.
40. Chambers TM, Kahan S, Camanda JF, Scheurer M, Airewele GE. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola. Pediatr Blood Cancer. 2018;65:27365.
41. Inusa BPD, Wale A, Hassan AA et al. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.2018;7:1-9.
42. Akingbola TS, Tayo B, Saraf SL, et al. Low fixed dose hydroxyurea for the treatment of adults with sickle cell disease in Nigeria. Blood. 2017;130:981.